The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Amicus Therapeutics Inc shares valued at $846,011 were sold by Campbell Bradley L on Dec 15 ’25. At $10.86 per share, Campbell Bradley L sold 77,926 shares. The insider’s holdings dropped to 1,129,782 shares worth approximately $12.43 million following the completion of this transaction.
Also, Clark David Michael sold 25,643 shares, netting a total of over 282,073 in proceeds. Following the sale of shares at $11.00 each, the insider now holds 271,332 shares.
Before that, BRADLEY CAMPBELL had added 77,926 shares to its account. In a trade valued at $822,119, the Director bought Amicus Therapeutics Inc shares for $10.55 each.
As published in their initiating research note from Citigroup on December 17, 2025, Amicus Therapeutics Inc [FOLD] has been a Buy and the price target has been revised to $17. Analysts at Needham upgraded the stock from ‘”a Hold”‘ to ‘”a Buy”‘ outlook in a report released in mid September. As of July 17, 2025, Morgan Stanley has increased its “an Equal-weight” rating to a “an Overweight” for FOLD. Earlier on December 13, 2024, Morgan Stanley downgraded its rating. Their new recommendation was “an Equal-weight” for FOLD stock which previously was a “an Overweight”.
Analyzing FOLD Stock Performance
On last trading session, Amicus Therapeutics Inc [NASDAQ: FOLD] rose 1.01% to $11.0. The stock’s lowest price that day was $10.92, but it reached a high of $11.1367 in the same session. During the last five days, there has been a surge of approximately 11.68%. Over the course of the year, Amicus Therapeutics Inc shares have jumped approximately 17.52%. Shares of the company reached a 52-week high of $11.14 on 12/15/25 and a 52-week low of $5.51 on 06/25/25.
Support And Resistance Levels for Amicus Therapeutics Inc (FOLD)
According to the 24-hour chart, there is a support level at 10.89, which, if violated, would cause prices to drop to 10.79. In the upper region, resistance lies at 11.12. The next price resistance is at 11.24. RSI (Relative Strength Index) is 79.70 on the 14-day chart, showing overbought technical sentiment.
Is Amicus Therapeutics Inc subject to short interest?
Stocks of Amicus Therapeutics Inc saw a sharp rise in short interest on 2025-11-28 jumping by 2.26 million shares to 19.31 million. Data from Yahoo Finance shows that the short interest on 2025-10-31 was 17.05 million shares. A jump of 11.69% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 3.66 of the overall float, the days-to-cover ratio (short ratio) jumped to 3.66.
Which companies own the most shares of Amicus Therapeutics Inc (FOLD)?
In terms of Amicus Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 14 in the next 12 months, up nearly 28.56% from the previous closing price of $10.89. Analysts anticipate Amicus Therapeutics Inc stock to reach 14 by 2025, with the lowest price target being 14. In spite of this, 5 analysts ranked Amicus Therapeutics Inc stock as Buy at the end of 2025. On September 06, 2024, Jefferies assigned a price target of “a Buy” to the stock and initiated coverage with a $18.
